Theravance Biopharma Inc expected to post a loss of 21 cents a share - Earnings Preview

Theravance Biopharma

24/02/2025 21:31

* Theravance Biopharma Inc  TBPH.OQ   TBPH.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
26 for the period ending December 31 2024
    * The George Town Grand Cayman-based  company is expected to
report a 2.7% decrease in revenue to $17.091 million from $17.57
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Theravance Biopharma Inc
is
for a loss of 21 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Theravance
Biopharma Inc is $12.50​, above​ its last closing price
of $9.32. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.24       -0.23      -0.26     Missed  -12.6
 Jun. 30 2024  -0.22       -0.21      -0.28     Missed  -35.6
 Mar. 31 2024  -0.22       -0.25      -0.24     Beat    5.5​
 Dec. 31 2023  -0.17       -0.15      -0.17     Missed  -14.3
 ​​Sep.        -0.22       -0.21      -0.17     Beat    18.9
 30 2023                                                
 Jun. 30 2023  -0.22       -0.21      -0.28     Missed  -33.3​
 Mar. 31 2023  -0.25       -0.25      -0.35     Missed  -42.1
 Dec. 31 2022  -0.17       -0.17      -0.15     Beat    13
 This summary was machine generated February 24 at 21:31 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)